AstraZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England research site, a ...

Not all cardiac arrests can be treated with an electric shock. In fact, most of them—about 80%—are ineligible for ...

The pause is the latest blow to the U.K.’s biotech industry, which is still reeling from Merck’s recently announced R&D ...

Philips and Masimo are renewing their years-long collaboration in patient monitoring, with what they describe as an expanded ...

Like approved Alzheimer’s meds Kisunla (donanemab) and Leqembi (lecanemab), as well as the discontinued Aduhelm (aducanemab), ...

With its head of U.S. business Julie Kim sliding up to the CEO spot next June, Takeda has locked in a replacement in Rhona ...

Researchers at Mass General Brigham in Boston have designed a custom gene editing technique that corrected the mutation ...

Exact Sciences has launched its long-awaited blood test designed to detect the early stages of multiple tumors, with a plan ...

Arrowhead Pharmaceuticals has launched legal action against Ionis Pharmaceuticals, aiming to neutralize Ionis' claim that Arrowhead's potential rival to Tryngolza breaches a patent. | Arrowhead ...

FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission (SEC) to address allegations that the ...

Capsida Biotherapeutics has paused a gene therapy trial after the first patient died. | Capsida Biotherapeutics has paused a ...

LB Pharmaceuticals’ decision to break cover and go public seems to have paid off, with the company bumping up the number of shares on offer for its Nasdaq listing this morning. | LB Pharmaceuticals’ ...